Bond Biosciences

Focus: Bond Biosciences is a private biotechnology company focused on developing treatments for ion-related diseases, currently headquartered in Parkville, Missouri. The company is in early-stage development with a focused pipeline targeting rare genetic disorders.

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Funding Stage

PRIVATE

Open Jobs

About Bond Biosciences

AI assessmentNot Hiring

No open roles listed right now. Follow Bond Biosciences to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

2 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

BBI-001

Hereditary Hemochromatosis

Phase 1

Clinical Trials (1)

NCT05238207A Study to Evaluate BBI-001 in Hereditary Haemochromatosis (HH) Patients and Iron Deficient Volunteers

Phase 1

Help build intelligence for Bond Biosciences

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity to shape a company focused on ion channel biology, a validated but underexplored therapeutic area
Potential to work on first-in-class or best-in-class therapies for rare, high-unmet-need diseases like hereditary hemochromatosis
Flat organizational structure typical of private biotech allows direct impact on drug development strategy and clinical decisions

Watch Out For

Zero current job openings and no disclosed funding information creates uncertainty around hiring plans and company stability
Very early pipeline (Phase 1/2 stage only) means 5–7+ years to potential commercialization and high risk of clinical failure
Limited public visibility on financials, employee count, or recent milestones makes due diligence difficult

Generated by Claude from Bond Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

BBI-001

Hereditary Hemochromatosis

Phase 1/2

Clinical Trials (1)

NCT07371793A Study to Evaluate BBI-001 in Healthy Volunteers and in Patients With Hereditary Hemochromatosis

Phase 1/2

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 2 clinical trials

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo